Seeking Alpha

Akorn acquires eye drop solutions from Merck in $52.8M deal

  • Niche generic maker Akorn (AKRX +4.5%) rises after announcing the acquisition of the U.S. rights to AzaSite, COSOPT, COSOPT PF (they're all eye drop solutions) from Merck (MRK +0.3%) for $52.8M.
  • The move "further expands [our] position as a leader in U.S. ophthalmology products," AKRX CEO Raj Rai says.
  • For MRK, the deal is consistent with its "ongoing strategy to sharpen commercial focus and improve operational effectiveness." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector